|
Schizophrenia
|
0.340 |
AlteredExpression
|
disease |
BEFREE |
In frontal cortex we observed: 1) reduced expression of 120 kDa form of APP in subjects with schizophrenia and bipolar disorder; 2) reduced expression of 61 kDa and 33k Da forms of STEP in subjects with schizophrenia; 3) reduced expression of 88 kDa form of APP in subjects with bipolar disorder; and 3) trends for reduced expression of 88 kDa form of APP and homer 1 in subjects with schizophrenia and bipolar disorder, respectively.
|
25956630 |
2015 |
|
Schizophrenia
|
0.340 |
Biomarker
|
disease |
BEFREE |
Taken together, our findings suggest that STEP(61) accumulation may contribute to the pathophysiology of SZ.
|
22781170 |
2012 |
|
Schizophrenia
|
0.340 |
Biomarker
|
disease |
PSYGENET |
Taken together, our findings suggest that STEP(61) accumulation may contribute to the pathophysiology of SZ.
|
22781170 |
2012 |
|
Schizophrenia
|
0.340 |
Biomarker
|
disease |
BEFREE |
In this study, we examined the association of the protein tyrosine phosphatase non-receptor 5 (PTPN5) gene, which encodes for STEP, with both schizophrenia and cognitive functioning in the Israeli Jewish population.
|
22555153 |
2012 |
|
Schizophrenia
|
0.340 |
Biomarker
|
disease |
BEFREE |
Previous work has demonstrated that the STriatal-Enriched protein tyrosine Phosphatase 61 kDa (STEP<sub>61</sub>) is elevated in human SZ postmortem cortical samples and after administration of psychotomimetics to cultures or mice.
|
28466270 |
2018 |
|
Schizophrenia
|
0.340 |
Biomarker
|
disease |
PSYGENET |
In this study, we examined the association of the protein tyrosine phosphatase non-receptor 5 (PTPN5) gene, which encodes for STEP, with both schizophrenia and cognitive functioning in the Israeli Jewish population.
|
22555153 |
2012 |
|
Transient Ischemic Attack
|
0.200 |
Therapeutic
|
disease |
RGD |
Neuroprotective role of a brain-enriched tyrosine phosphatase, STEP, in focal cerebral ischemia.
|
24198371 |
2013 |
|
Transient Ischemic Attack
|
0.200 |
Biomarker
|
disease |
RGD |
Neuroprotective role of a brain-enriched tyrosine phosphatase, STEP, in focal cerebral ischemia.
|
24198371 |
2013 |
|
Hypoxia-Ischemia, Brain
|
0.200 |
Biomarker
|
disease |
RGD |
Hypoxia-ischemia in perinatal rat brain induces the formation of a low molecular weight isoform of striatal enriched tyrosine phosphatase (STEP).
|
10537057 |
1999 |
|
Myopia
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Detection and interpretation of shared genetic influences on 42 human traits.
|
27182965 |
2016 |
|
Huntington Disease
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
We used protein-encoding and shRNA-expressing lentiviral vectors to evaluate the effects of RGS2, RASD2, STEP and NNAT downregulation in HD.
|
21779398 |
2011 |
|
Huntington Disease
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Alterations in STriatal-Enriched protein tyrosine Phosphatase expression, activation, and downstream signaling in early and late stages of the YAC128 Huntington's disease mouse model.
|
24588402 |
2014 |
|
Huntington Disease
|
0.030 |
Biomarker
|
disease |
BEFREE |
In conclusion, our results show that deletion of STEP has a beneficial effect on motor coordination and cognition in a mouse model of HD suggesting that STEP inhibition could be a good therapeutic strategy in HD patients.
|
30176350 |
2018 |
|
Alzheimer's Disease
|
0.020 |
Biomarker
|
disease |
BEFREE |
Accumulating evidence over the past decade indicates that STEP dysregulation contributes to the pathophysiology of several neuropsychiatric disorders, including Alzheimer's disease, schizophrenia, fragile X syndrome, epileptogenesis, alcohol-induced memory loss, Huntington's disease, drug abuse, stroke/ischemia, and inflammatory pain.
|
22090472 |
2012 |
|
Alzheimer's Disease
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Excessive activity of striatal-enriched protein tyrosine phosphatase (STEP) in the brain has been detected in numerous neuropsychiatric disorders including Alzheimer's disease.
|
29116812 |
2017 |
|
Bipolar Disorder
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
We then combined our sample with another Nordic case-control sample (n = 435/11,491) from Iceland, and added results from the Wellcome Trust Case Control Consortium (WTCCC) (n = 1,868/2,938) and the STEP-UCL/ED-DUB-STEP2 study (n = 2,558/3,274) in a meta-analysis which revealed a P-value of 1.2 × 10(-5) for association between PALB2 SNP rs420259 and BD (n = 5,547/20,241).
|
20872766 |
2010 |
|
Bipolar Disorder
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
In frontal cortex we observed: 1) reduced expression of 120 kDa form of APP in subjects with schizophrenia and bipolar disorder; 2) reduced expression of 61 kDa and 33k Da forms of STEP in subjects with schizophrenia; 3) reduced expression of 88 kDa form of APP in subjects with bipolar disorder; and 3) trends for reduced expression of 88 kDa form of APP and homer 1 in subjects with schizophrenia and bipolar disorder, respectively.
|
25956630 |
2015 |
|
Amnesia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Accumulating evidence over the past decade indicates that STEP dysregulation contributes to the pathophysiology of several neuropsychiatric disorders, including Alzheimer's disease, schizophrenia, fragile X syndrome, epileptogenesis, alcohol-induced memory loss, Huntington's disease, drug abuse, stroke/ischemia, and inflammatory pain.
|
22090472 |
2012 |
|
Malignant neoplasm of breast
|
0.010 |
Biomarker
|
disease |
BEFREE |
Further, PTPN5 expression is strongly associated with good clinical outcome in tamoxifen treated human breast cancer patients suggesting that PTPN5 may represent a novel biomarker of tamoxifen response in human breast cancer.
|
29590203 |
2018 |
|
Mental Depression
|
0.010 |
Biomarker
|
disease |
BEFREE |
Earlier we showed that striatal-enriched protein tyrosine phosphatase (STEP) inhibitor - 8-(trifluoromethyl)-1,2,3,4,5-benzopentathiepin-6-amine hydrochloride (TC-2153) affects both the brain serotoninergic system and the brain-derived neurotropic factor that are known to be involved in the psychopathology of depression.
|
30367948 |
2018 |
|
Depressive disorder
|
0.010 |
Biomarker
|
disease |
BEFREE |
Earlier we showed that striatal-enriched protein tyrosine phosphatase (STEP) inhibitor - 8-(trifluoromethyl)-1,2,3,4,5-benzopentathiepin-6-amine hydrochloride (TC-2153) affects both the brain serotoninergic system and the brain-derived neurotropic factor that are known to be involved in the psychopathology of depression.
|
30367948 |
2018 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.010 |
Biomarker
|
disease |
BEFREE |
Artefactual inflation of type 2 diabetes prevalence in WHO STEP surveys.
|
30706604 |
2019 |
|
Fragile X Syndrome
|
0.010 |
Biomarker
|
disease |
BEFREE |
These studies suggest that STEP inhibition may have therapeutic benefit in FXS.
|
28943283 |
2018 |
|
Neuroblastoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
A<sub>2A</sub> Rs modulate STEP activity also in the SH-SY5Y neuroblastoma cell line, where a calcium-dependent calcineurin/PP1 pathway was found to play a major role.
|
31520531 |
2020 |
|
Parkinson Disease
|
0.010 |
Biomarker
|
disease |
BEFREE |
Relevant to PD, STEP61 accumulates in the striatum of human sporadic PD and in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned mice.
|
25583483 |
2015 |